Search results: (10000)
News Panitumumab in 1st Line in Older Patients – Results of the PANDA Study
The phase II PANDA study evaluated the regimens FOLFOX + panitumumab versus 5-FU + panitumumab in the 1st line treatment of patients with wt-RAS/BRAF metastatic colorectal cancer (mCRC).
News Current Data on the Safety Profile of Baricitinib in the Treatment of Rheumatoid Arthritis
Baricitinib was approved for the treatment of rheumatoid arthritis (RA) in 2017, making it essential and relevant to monitor its safety profile in clinical practice. The analysis of data collected over 8.4 years presented below provides current insights.
News Sport Therapy as Part of Hemophilia Management
A study by authors from the University of Wuppertal in Germany specifically examined the impact of a half-year programmed sport therapy on the subjective physical performance and quality of life of individuals with hemophilia.
News Enoxaparin in Weight-Based Dosing for Thromboprophylaxis in Hospitalized Cancer Patients
Cancer patients are at higher risk of developing thromboembolic disease during hospitalization. Currently, there is not enough evidence supporting the efficacy and safety of the standard fixed dose of low molecular weight heparin in individuals at high risk of thromboembolic disease. Therefore, a Phase II clinical study evaluated the efficacy and safety of weight-adjusted dosing in these patients.
News Two Is Not Enough: Efficacy of Alemtuzumab in Subsequent Cycles
The goal of the recent pooled analysis of the CARE-MS and TOPAZ study results published in the journal Multiple Sclerosis was to evaluate the efficacy and safety of alemtuzumab in patients with relapsing-remitting multiple sclerosis (RRMS) who received alemtuzumab in additional cycles beyond the first 2 cycles.
News Efficacy of Romiplostim in Children with Persistent or Chronic ITP
The effect of the thrombopoietin receptor agonist romiplostim in adult patients with immune thrombocytopenia (ITP) is well known. Equally important, however, are data on its treatment in children — presented by a study whose results were published in the journal Lancet.
News Experiences with AHA in Two Czech Centers and Risk Factor Evaluation
This summer, the journal Haemophilia published the results of an analysis of data from a relatively large Czech cohort of patients with acquired hemophilia A (AHA). The goal was to identify risk factors associated with early death and AHA relapse. Additionally, the authors addressed the question of the effect of higher doses of corticosteroids on treatment outcomes and patient mortality.
News Does Ixekizumab Have Long-term Effects on Improving Psoriatic Arthritis Symptoms?
The extension of the SPIRIT-P2 study brought results of ixekizumab in patients with psoriatic arthritis (PsA) after 3 years of use. The data below were presented as a poster presentation at the annual congress of the European League Against Rheumatism (EULAR), which was held virtually in June 2020.
News Shared Decision-Making on Kidney Function Replacement
Peritoneal dialysis (PD) is not a new development, but its significance is becoming increasingly recognized. Until recently, we may not have fully appreciated its value, but in light of the global threat posed by the current pandemic, its importance is starkly clear. PD is an accessible solution designed for home care and allows patients to avoid visits to healthcare facilities to some extent.
News ADCT – a simple tool for self-diagnosis of patients with severe atopic dermatitis
Atopic dermatitis (AD) is a chronic inflammatory disease not only of childhood. It can negatively affect the quality of life despite being treatable. Control and management of the disease in different areas of life can be easily evaluated using the ADCT questionnaire.
News Dupilumab in the Treatment of Adolescent Patients with Severe and Refractory Atopic Dermatitis
An open multicenter study evaluating dupilumab in the treatment of moderate to severe atopic dermatitis in adolescents confirmed its long-term efficacy and safety in this age group. In addition to its results, we also summarize information on dosing and reimbursement conditions in the Czech Republic for the age group 12-18 years.
News Did the Extension of the TOWER Study Confirm the Position of Teriflunomide?
The results of the TOWER study extension were published this August in the prestigious journal Multiple Sclerosis and Related Disorders. So, how did teriflunomide fare in this recent evaluation for the treatment of relapsing-remitting multiple sclerosis?
News Diagnosis, Treatment, and Outcomes Achieved in Patients with Non-Small-Cell Lung Cancer in Central Europe
In June 2020, the journal Radiology and Oncology published the results of an analysis of data from patients with stage III non-small-cell lung cancer (NSCLC) from a Central European registry. A large team led by Czech experts focused on the diagnostic and therapeutic procedures used and the treatment results achieved in real-world practice.
News COVID-19: Specifics of Care for Individuals with Congenital Bleeding Disorders
The COVID-19 pandemic has significantly impacted nearly all medical fields. Alongside direct care focused on seriously ill patients, the pandemic also affects the care of chronic patients, including those with hemophilia. However, there is currently not much specific data available regarding experiences with COVID-19 in patients with hemophilia. The specifics of congenital bleeding disorders, especially in relation to the severe course of COVID-19, are discussed by Italian authors in their article published in the journal Seminars in Thrombosis and Hemostasis.
News Safety Profile of Antiemetic Therapy in Patients Preparing for Hematopoietic Stem Cell Transplantation
An observational study conducted at a university clinic in Barcelona investigated the safety of the fixed combination of palonosetron and netupitant in patients preparing for hematopoietic stem cell transplantation.
News Brigatinib vs. Crizotinib in the Treatment of ALK-Positive NSCLC – Results of the Second Interim Analysis of the ALTA-1L Study
The anaplastic lymphoma kinase inhibitor brigatinib demonstrated superiority over crizotinib in the first interim analysis of the ALTA-1L study in terms of progression-free survival and improvement in health-related quality of life in patients with non-small cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK) gene rearrangement. The second interim analysis results published in 2020 confirm these primary findings.
News Good Efficacy of Brigatinib After Failure of 2nd Generation ALK Inhibitors
Brigatinib is commonly used in the treatment of ALK-positive non-small cell lung cancer (NSCLC) in the 2nd line after progression on a 1st-generation ALK inhibitor, crizotinib. American scientists in a phase II study focused on the efficacy of brigatinib in the treatment of patients with advanced NSCLC who had progressed on 2nd-generation ALK inhibitors.
News Self-Administration of Romiplostim in Chronic Immune Thrombocytopenia: Analysis of 3 Studies
A post hoc analysis of 3 clinical studies showed that in adult patients with chronic immune thrombocytopenia (ITP), self-administration of romiplostim achieves comparable efficacy and safety as when the drug is administered by a healthcare professional.
News The Role of the Physiotherapist in the Management of Hemophilia – Defining a New Normal
Historically, the role of physiotherapy in hemophiliacs was primarily to assist patients who developed severe hemophilic arthropathies resulting from recurrent untreated or inadequately treated bleeding. Today, it has also shifted to prevention as such, although it still plays a role in significant joint bleeding or when a hemophiliac needs to undergo surgery.
News Improvement of Physical Functions in Patients with COPD in Routine Clinical Practice Using the Fixed Combination of Tiotropium/Olodaterol
The increase in exercise capacity using the fixed combination of tiotropium and olodaterol in the Respimat inhaler has already been demonstrated in clinical studies for patients with chronic obstructive pulmonary disease (COPD). Italian authors evaluated its benefit under real-world conditions and also focused on patient satisfaction with the inhaler.
News Thromboprophylaxis with Enoxaparin Reduces Mortality in Patients Hospitalized with COVID-19
Severe acute respiratory syndrome caused by COVID-19 is associated with a hypercoagulable state and an increased risk of thrombotic events. Since the beginning of the pandemic, thromboprophylaxis has been recommended for these patients despite initial insufficient evidence. In the fall of 2020, an observational study was published confirming the beneficial effect of enoxaparin on reducing mortality and the risk of ICU admission in patients with severe COVID-19.
News Benefit of ixazomib in patients with relapsed/refractory multiple myeloma in routine clinical practice
The results of treating relapsed or refractory multiple myeloma in real-world routine clinical practice were published by a broad team of Czech experts in the journal BMC Cancer.
News Tolerability and Efficacy of Eye Drops with and without Preservatives − A Comparison in Routine Clinical Practice
Insufficient patient compliance due to intolerance of the ocular preparation is a major reason for changing treatment, such as switching to preservative-free drops. The aim of the international prospective and observational study was to assess the efficacy and local tolerability within a one-year therapy of preservative-free latanoprost compared to drops containing preservatives and to determine patient satisfaction at the midpoint of treatment. During the monitoring, 3 examinations were planned: one at the study entry and two follow-up visits (at 6 and 12 months).
News In vivo monitoring of corneal changes in patients treated with and without preservative-containing glaucoma medications
A study published last year by Italian authors monitored structural changes in the corneas of patients treated with preservative-free glaucoma medication for 3 years using confocal microscopy and compared them with changes observed in patients treated with preservative-containing medications.
News Minimum and Optimal Factor Levels in Physically Active Hemophiliacs
Authors of a recently published study attempted to determine the value of minimum and optimal levels of coagulation factors in patients with severe hemophilia who engage in physical activities.